Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2026 10:00 ET | Source: National Association of Realtors®

NAR Pending Home Sales Report Shows 9.3% Decrease in December

Washington, D.C., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Pending home sales in December decreased by 9.3% from the prior month and 3.0% year over year, according to the National Association of REALTORS®...
January 21, 2026 08:50 ET | Source: Inspira Technologies

Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders

RA'ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...
January 21, 2026 08:30 ET | Source: Entera Bio

Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook

Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1...
January 21, 2026 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
January 20, 2026 08:00 ET | Source: Posit Science

How an Avalanche of Science Buried Brain Exercise Skeptics in 2025

SAN FRANCISCO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brain training reached a turning point in 2025, after years of accumulating evidence snowballed into an avalanche of scientific validation. A surge...
January 20, 2026 08:00 ET | Source: Nasus Pharma, Ltd.

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved the 100 pg/ml plasma threshold...
January 16, 2026 07:00 ET | Source: Summit Royalties Ltd.

Summit Royalties Announces Trading on the OTCQB Venture Market and Participation in TSXV Bell Opening Ceremony

Summit Begins Trading on OTCQB
January 14, 2026 16:01 ET | Source: 374Water

374Water Regains Compliance with NASDAQ Listing Requirement

374Water Regains Compliance with NASDAQ Listing Requirement
January 14, 2026 10:00 ET | Source: National Association of Realtors®

NAR Existing-Home Sales Report Shows 5.1% Increase in December

Washington, D.C., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Existing-home sales increased by 5.1% in December, according to the National Association of REALTORS® Existing-Home Sales report. The report...
January 14, 2026 07:00 ET | Source: OTC Markets

OTC Markets Group Welcomes Cannara Biotech Inc. to OTCQX

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cannara Biotech...